Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31055397 | 0.73 | L3MBTL1 (0.72) | SMN1; SMN2HTTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL12760632 | 0.73 | L3MBTL1 (0.72) | SMN1; SMN2HTTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL31055430 | 0.73 | KMT2A (0.78) | SMN1; SMN2HTTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL4743364 | 0.72 | ALDH1A1 (0.46) | SMN1; SMN2HTTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL13761476 | 0.72 | ALDH1A1 (0.59) | SMN1; SMN2HTTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL401199 | 0.71 | L3MBTL1 (0.64) | SMN1; SMN2HTTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL13753288 | 0.71 | ALDH1A1 (0.61) | SMN1; SMN2HTTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL13753287 | 0.71 | ALDH1A1 (0.61) | SMN1; SMN2HTTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL266386 | 0.70 | ALDH1A1 (0.69) | SMN1; SMN2HTTL3MBTL1ALDH1A1NPC1 | |
| SCHEMBL9824905 | 0.70 | POLB (0.51) | SMN1; SMN2L3MBTL1ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| EP-2027096-B1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | Bayer Pharma AG (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| EP-2027096-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | Bayer HealthCare AG (DE) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134862-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER HEALTHCARE AG (DE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | SMN1; SMN2 4777/4885HTT 1997/4885L3MBTL1 4160/4885 |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | AVPR2, AVPR1A, AVPR1B | SMN1; SMN2 4777/4885HTT 1997/4885L3MBTL1 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.